Navigation Links
Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
Date:2/25/2010

CORAL GABLES, Fla., Feb. 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it will be making a presentation today at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum being held at the Hyatt Embarcadero Hotel in San Francisco.  For additional program information, please visit www.epilepsy.com/node/985708.  As previously reported, the Company will present an overview of CPP-115, Catalyst's development stage anticonvulsant compound, as a potential treatment for a variety of epileptic conditions, including complex partial seizures and infantile spasms (West Syndrome). Furth
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015  Eli Lilly and Company (NYSE: ... today announced that they have entered into a clinical ... of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in ... 2 antiangiogenic cancer medicine. The planned study will assess ... solid tumors. The Phase I study is ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... - Initial clinical trial results suggesting safety and ... the AACR-NCI-EORTC International Conference -, BRANFORD, Conn., ... a clinical-stage biopharmaceutical company focused on,oncology, announced that ... CR011-,vcMMAE, an antibody-drug conjugate (ADC) being developed for ...
... of Two Major Clinical Studies TAX 323 and ... Sanofi-aventis,announced today that results of two clinical ... to cisplatin and,5- fluorouracil for induction therapy, significantly ... squamous cell carcinoma of,the head and neck (SCCHN) ...
Cached Medicine Technology:CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 2CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 3CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 4CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 5CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7
(Date:5/30/2015)... 30, 2015 "Despite having the most ... get better health outcomes than people in other developed ... always safe" states author Dr. John Patrick in his ... Unraveling and Solving the Complexities of Healthcare, John ... to the healthcare policy debate will understand. He arrives ...
(Date:5/30/2015)... 30, 2015 Twelve of the nation’s ... their peers as the 2015 Giants of Cancer ... the Chicago Illuminating Company last night. The awardees included ... for landmark achievements in translational research, gene therapy, immuno-oncology ... of cancer treatment. , Honorees were introduced and celebrated ...
(Date:5/30/2015)... 30, 2015 AVT, the world leader ... is joining forces with leading proofing solutions provider Global ... worldwide printing market. , Under the agreement, ... engine for its offline inspection solutions, which are customized ... and its varying production workflow setups and printing applications. ...
(Date:5/30/2015)... You've probably heard that using cotton swabs ... However, have you found a better way to remove ear ... exactly what you need. , They developed SUNDENG EAR CLEANER ... dead, dry skin from the ears. What's more, it is ... on the market today for children and adults of all ...
(Date:5/30/2015)... 2015 Promising clinical trial results presented ... Meeting 2015 show activity of the investigational anti-cancer agent ... against brain metastases and in another case in overall ... "I am thrilled to have been able to offer ... She didn't have any other great treatment options that ...
Breaking Medicine News(10 mins):Health News:"Health Attitude", a new book by Dr. John R. Patrick, explains the American healthcare system, what is wrong with it, and how to fix it. 2Health News:"Health Attitude", a new book by Dr. John R. Patrick, explains the American healthcare system, what is wrong with it, and how to fix it. 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3
... ZEELAND, Mich., Dec. 19 Herman Miller, Inc.,announced ... Inc.,a Seattle-based manufacturer of healthcare furnishings. The transaction ... the conclusion of due,diligence. Terms of the transaction ... of healthcare furnishings, with an emphasis,on seating products ...
... Delta Dental of Illinois has made,a ... Illinois at Chicago,College of Dentistry to modernize ... are complete, the clinic will be named ... Clinic., (Photo: http://www.newscom.com/cgi-bin/prnh/20071219/AQW128 ), ...
... SCHAUMBURG, Ill., Dec. 19 The American,Veterinary Medical ... the Veterinary Workforce Grant Program (VWGP) as part ... program will help ensure an,adequate supply of public ... "The Farm Bill is vitally important to rural ...
... new molecular pathway that appears to be involved in ... 100 million people around the world and is caused ... Blocking this pathway could be a treatment for the ... failure. The research teams findings will appear in ...
... a big impact on behavior, studies show , , WEDNESDAY, Dec. ... its 1 trillion cells, looking for perhaps only one or ... a trio of new studies says. , The research, conducted ... Nature , could rewrite the textbooks on just how ...
... Researchers here have figured out a way to use ... a new drug combination actually is against some forms of ... looked at ATLL, adult T-cell lymphoma and leukemia, a form ... disease,s progress, and where the patients, prognosis is generally poor. ...
Cached Medicine News:Health News:Herman Miller, Inc., Announces Strategic Acquisition of Brandrud Furniture, Inc. to Expand Its Product Offerings and Competitive Position in the Healthcare Furnishings Sector 2Health News:Herman Miller, Inc., Announces Strategic Acquisition of Brandrud Furniture, Inc. to Expand Its Product Offerings and Competitive Position in the Healthcare Furnishings Sector 3Health News:Delta Dental of Illinois Announces Major Gift to University of Illinois at Chicago College of Dentistry 2Health News:AVMA Lauds Senators for Approving 2007 Farm Bill Legislation that Includes the Veterinary Workforce Grant Program 2Health News:Receptor protein appears to be key in breakdown of kidney filtration 2Health News:Receptor protein appears to be key in breakdown of kidney filtration 3Health News:Brain Cells More Powerful Than You Think 2Health News:Brain Cells More Powerful Than You Think 3Health News:Brain Cells More Powerful Than You Think 4Health News:Firefly genes allow testing of new therapy against lymphoma 2Health News:Firefly genes allow testing of new therapy against lymphoma 3
... Built-in, motor-driven internal calibration mass for ... Self-Calibration when temperature change detected and ... weighing parameters, plug-in peripherals, and easy ... this balance series highly accurate and ...
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... DNA sequencing reagents including linear polyacrylamide ... cyanine-based infrared dyes- coupled with online denaturation. ... meaningful raw data, and higher-quality final analyses. ... 8800 to resolve complex sequences, filling in ...
... 3100 system offers continuous, unattended operation ... separation and detection, and data analysis. ... and importing sample information, the operator ... Run command. The instrument requires no ...
Medicine Products: